## **Dimitrios Vassilopoulos**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8276686/publications.pdf

Version: 2024-02-01

152 papers 4,333 citations

30 h-index 61 g-index

154 all docs

154 docs citations

154 times ranked 6932 citing authors

#	Article	IF	Citations
1	Hepatitis B e antigen–negative chronic hepatitis B. Hepatology, 2001, 34, 617-624.	7.3	462
2	Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir. Gastroenterology, 2012, 143, 629-636.e1.	1.3	286
3	Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Annals of the Rheumatic Diseases, 2014, 73, 1854-1863.	0.9	229
4	Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Annals of the Rheumatic Diseases, 2006, 65, 983-989.	0.9	195
5	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the Rheumatic Diseases, 2021, 80, 1137-1146.	0.9	151
6	Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Annals of the Rheumatic Diseases, 2010, 69, 1352-1355.	0.9	133
7	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2527-2539.	5.6	122
8	An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmunity Reviews, 2019, 18, 751-760.	5.8	115
9	Musculoskeletal Infections in Patients with Human Immunodeficiency Virus Infection. Medicine (United States), 1997, 76, 284-294.	1.0	107
10	Defective CD3-Mediated Cell Death in Activated T Cells from Patients with Systemic Lupus Erythematosus: Role of Decreased Intracellular TNF- $\hat{l}\pm$ . Clinical Immunology and Immunopathology, 1996, 81, 293-302.	2.0	102
11	Hepatitis C virus infection and vasculitis: Implications of antiviral and immunosuppressive therapies. Arthritis and Rheumatism, 2002, 46, 585-597.	6.7	100
12	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International) Tj ETQq0 0 0 956-964.	) rgBT /Ove 1.8	erlock 10 Tf 50 98
13	Tregs restrain dendritic cell autophagy to ameliorate autoimmunity. Journal of Clinical Investigation, 2017, 127, 2789-2804.	8.2	92
14	Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. Arthritis Research and Therapy, 2008, 10, 215.	3.5	76
15	Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 2215-2217.	0.9	68
16	Management of rheumatic disease with comorbid HBV or HCV infection. Nature Reviews Rheumatology, 2012, 8, 348-357.	8.0	67
17	Low disease activityâ€"irrespective of serologic status at baselineâ€"associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Seminars in Arthritis and Rheumatism, 2018, 48, 467-474.	3.4	59
18	The effect of TNF-a antagonists on aortic stiffness and wave reflections: a meta-analysis. Clinical Rheumatology, 2018, 37, 515-526.	2.2	59

#	Article	IF	CITATIONS
19	Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Current Opinion in Rheumatology, 2007, 19, 619-625.	4.3	57
20	Comparison of Two Gamma Interferon Release Assays and Tuberculin Skin Testing for Tuberculosis Screening in a Cohort of Patients with Rheumatic Diseases Starting Anti-Tumor Necrosis Factor Therapy. Vaccine Journal, 2011, 18, 2102-2108.	3.1	57
21	Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). International Journal of Cardiology, 2012, 160, 66-68.	1.7	54
22	Anakinra. Journal of Cardiovascular Medicine, 2016, 17, 256-262.	1.5	54
23	Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Annals of the Rheumatic Diseases, 2013, 72, 308-310.	0.9	48
24	Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2015, 74, 1848-1853.	0.9	46
25	Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Antiviral Research, 2001, 52, 91-98.	4.1	45
26	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1013-1016.	0.9	43
27	Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Journal of Rheumatology, 2008, 35, 1271-6.	2.0	42
28	Rheumatic manifestations of hepatitis C infection. Current Rheumatology Reports, 2003, 5, 200-204.	4.7	38
29	The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges. Frontiers in Medicine, 2017, 4, 78.	2.6	38
30	Hepatitis B Reactivation in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2017, 43, 133-149.	1.9	34
31	Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2091264.	2.7	33
32	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatology International, 2020, 40, 1353-1360.	3.0	33
33	Extrahepatic immunological complications of hepatitis C virus infection. Aids, 2005, 19, S123-S127.	2.2	29
34	High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. Journal of General Virology, 2011, 92, 1343-1351.	2.9	29
35	Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology, 2014, 53, 195-196.	1.9	29
36	Gammalinolenic Acid and Dihomogammalinolenic Acid Suppress the CD3-Mediated Signal Transduction Pathway in Human T Cells. Clinical Immunology and Immunopathology, 1997, 83, 237-244.	2.0	28

#	Article	IF	CITATIONS
37	Is There a Place for Cardiovascular Magnetic Resonance Imaging in the Evaluation of Cardiovascular Involvement in Rheumatic Diseases?. Seminars in Arthritis and Rheumatism, 2011, 41, 488-496.	3.4	28
38	COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. Rheumatology International, 2022, 42, 31-39.	3.0	28
39	Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study. Clinical and Experimental Rheumatology, 2016, 34, 893-900.	0.8	28
40	A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States. Vaccine, 2021, 39, 6585-6590.	3.8	26
41	Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. American Journal of Medicine, 2004, 116, 601-605.	1.5	24
42	Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Seminars in Arthritis and Rheumatism, 2015, 45, 60-66.	3.4	24
43	Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis. Clinical Rheumatology, 2015, 34, 359-364.	2.2	24
44	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Research and Therapy, 2018, 20, 267.	3.5	24
45	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome <i>vs</i> rheumatoid arthritis: a multicenter, case-control study. Rheumatology, 2021, 60, 170-178.	1.9	24
46	Sensorineural hearing loss complicating severe rickettsial diseases: Report of two cases. Journal of Infection, 2008, 56, 74-76.	3.3	23
47	Clinical and financial burden of active lupus in Greece: a nationwide study. Lupus, 2016, 25, 1385-1394.	1.6	22
48	Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. Seminars in Arthritis and Rheumatism, 2021, 51, 137-143.	3.4	22
49	Usefulness of enzyme-linked immunosorbent assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Addendum. Journal of Rheumatology, 2008, 35, 1464.	2.0	22
50	The Natural Course of Chronic Hepatitis B Virus Infection and Its Management. Advances in Pharmacology, 2013, 67, 247-291.	2.0	21
51	Clinical significance of pleural effusions and association with outcome in patients hospitalized with a first episode of acute pericarditis. Internal and Emergency Medicine, 2019, 14, 745-751.	2.0	21
52	Hashimoto Encephalopathy with Pegylated Interferon Alfa-2b and Ribavirin. Annals of Pharmacotherapy, 2005, 39, 1745-1748.	1.9	20
53	Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. European Journal of Internal Medicine, 2011, 22, 572-575.	2.2	20
54	Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: A pilot observational prospective study. International Journal of Cardiology, 2020, 311, 77-82.	1.7	20

#	Article	IF	Citations
55	The Role of Colchicine in Pericardial Syndromes. Current Pharmaceutical Design, 2018, 24, 702-709.	1.9	20
56	Angioimmunoblastic T-Cell Lymphoma-Associated Arthritis. Journal of Clinical Rheumatology, 2005, $11$ , $326-328$ .	0.9	19
57	Hepatitis C Virus (HCV)-Related Cryoglobulinemia: Cryoglobulin Type and Anti-HCV Profile. Vaccine Journal, 2013, 20, 698-703.	3.1	19
58	Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience. Rheumatology, 2021, 60, 2375-2382.	1.9	19
59	Rheumatic manifestations of hepatitis. Current Opinion in Rheumatology, 2010, 22, 91-96.	4.3	18
60	Infections and vasculitis. Current Opinion in Rheumatology, 2017, 29, 17-23.	4.3	18
61	Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b. Scandinavian Journal of Gastroenterology, 2007, 42, 408-409.	1.5	17
62	High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clinical and Experimental Rheumatology, 2018, 36, 254-262.	0.8	17
63	Age―and sexâ€based differences in patients with acute pericarditis. European Journal of Clinical Investigation, 2021, 51, e13392.	3.4	16
64	Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies. Mediterranean Journal of Rheumatology, 2020, 31, 129.	0.8	16
65	Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. Rheumatology International, 2021, 41, 895-902.	3.0	15
66	Subacute Thyroiditis Presenting as Fever of Unknown Origin in a Patient With Rheumatoid Arthritis Under Etanercept Treatment. Journal of Clinical Rheumatology, 2010, 16, 88-89.	0.9	14
67	Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clinical and Experimental Rheumatology, 2017, 35, 579-585.	0.8	14
68	Immunization in patients with inflammatory rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2016, 30, 946-963.	3.3	13
69	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterranean Journal of Rheumatology, 2018, 29, 27-37.	0.8	13
70	Dialogue between the Brain and the Immune System in Inflammatory Arthritis. Annals of the New York Academy of Sciences, 2006, 1088, 132-138.	3.8	12
71	Interleukin-8 as a predictor of acute idiopathic pericarditis recurrences. A pilot study. International Journal of Cardiology, 2014, 172, e463-e464.	1.7	12
72	The landscape of acute pericarditis in Greece: Experience from a tertiary referral center. Hellenic Journal of Cardiology, 2019, 60, 139-140.	1.0	12

#	Article	IF	CITATIONS
73	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. Arthritis Research and Therapy, 2020, 22, 56.	3.5	12
74	Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis. Frontiers in Medicine, 2020, 7, 288.	2.6	12
75	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. Annals of the Rheumatic Diseases, 2021, 80, 65-70.	0.9	12
76	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. RMD Open, 2021, 7, e001724.	3.8	12
77	Effects of an aminosteroid inhibitor of phospholipase C-dependent processes on the TCR-mediated signal transduction pathway in human T cells. Clinical Immunology and Immunopathology, 1995, 77, 59-68.	2.0	11
78	Prevention of HBV reactivation in patients treated with biologic agents. Expert Review of Clinical Pharmacology, 2016, 9, 579-589.	3.1	11
79	Editorial commentary: Recurrent pericarditis in the era of interleukin-1 inhibition. Trends in Cardiovascular Medicine, 2021, 31, 275-276.	4.9	11
80	A risk score for pericarditis recurrence. European Journal of Clinical Investigation, 2021, 51, e13602.	3.4	11
81	Myelodysplastic syndrome presenting as acquired ichthyosis. European Journal of Internal Medicine, 2006, 17, 368-369.	2.2	10
82	Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B. Journal of Viral Hepatitis, 2008, 15, 817-826.	2.0	10
83	Severe rhabdomyolysis with hypoglycemia in an adult patient with carnitine palmitoyltransferase II deficiency. European Journal of Internal Medicine, 2008, 19, 289-291.	2.2	10
84	Prevalence of interatrial block in patients with Friedreich's Ataxia. International Journal of Cardiology, 2010, 145, 386-387.	1.7	10
85	Viral Hepatitis: Review of Arthritic Complications and Therapy for Arthritis in the Presence of Active HBV/HCV. Current Rheumatology Reports, 2013, 15, 319.	4.7	10
86	Predictors of switching from nonsteroidal anti-inflammatory drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic Journal of Cardiology, 2019, 60, 357-363.	1.0	10
87	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093713.	2.7	10
88	Modulation of Human T-Lymphocyte Plasma Membrane Ca +2 Permeability by Imidazole Antimycotics. Immunopharmacology and Immunotoxicology, 1996, 18, 237-245.	2.4	9
89	Unusual combination of paraneoplastic manifestations in a patient with metastatic gastrointestinal stromal tumor (GIST). Scandinavian Journal of Gastroenterology, 2008, 43, 1012-1015.	1.5	9
90	Hypocomplementemia is associated with more severe renal disease and worse renal outcomes in patients with ANCA-associated vasculitis: a retrospective cohort study. Renal Failure, 2020, 42, 845-852.	2.1	9

#	Article	IF	CITATIONS
91	Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment. Pathogens and Immunity, 2020, 5, 34.	3.1	9
92	Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series. Annals of the Rheumatic Diseases, 2022, 81, 1477-1479.	0.9	9
93	Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients. Frontiers in Immunology, 2017, 8, 1967.	4.8	8
94	Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease. RMD Open, 2020, 6, e001303.	3.8	8
95	Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. Clinical Rheumatology, 2020, 39, 3643-3652.	2.2	8
96	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology, 2021, 60, 2223-2230.	1.9	8
97	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 539-548.	3.0	8
98	First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. Scandinavian Journal of Gastroenterology, 2007, 42, 784-785.	1,5	7
99	Preventive influenza vaccination for patients with rheumatoid arthritis. A need for an international campaign. Clinical Rheumatology, 2009, 28, 103-104.	2.2	7
100	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofab588.	0.9	7
101	SELECTED DRUG COMPLICATIONS AND TREATMENT CONFLICTS IN THE PRESENCE OF COEXISTENT DISEASES. Rheumatic Disease Clinics of North America, 1999, 25, 745-777.	1.9	6
102	Complex management issues: management of HCV in the atypical patient. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2000, 14, 277-291.	2.4	6
103	Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. Arthritis Research and Therapy, 2021, 23, 90.	3.5	6
104	Transforming Growth Factor- $\hat{l}^21/S$ mad Signaling in Glomerulonephritis and Its Association with Progression to Chronic Kidney Disease. American Journal of Nephrology, 2021, 52, 653-665.	3.1	6
105	<i>Pneumocystis Jirovecii</i> Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review. Mediterranean Journal of Rheumatology, 2019, 30, 167.	0.8	6
106	Watermelon stomach and familial Mediterranean fever. American Journal of Gastroenterology, 2001, 96, 2512-2513.	0.4	5
107	Patients' and Doctors' Beliefs about Treatment and Long-Term Adherence in Rheumatic Diseases. Mediterranean Journal of Rheumatology, 2020, 31, 152.	0.8	5
108	Rheumatologic manifestations of HIV-l and HTLV-l infections. Cleveland Clinic Journal of Medicine, 1998, 65, 436-441.	1.3	5

#	Article	IF	Citations
109	Telbivudine in the treatment of chronic hepatitis B. Expert Review of Gastroenterology and Hepatology, 2008, 2, 13-22.	3.0	4
110	Chronic Hepatitis B and D., 0,, 26-38.		4
111	Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?. Current Hepatology Reports, 2014, 13, 256-263.	0.9	4
112	Combined brain and heart magnetic resonance imaging in systemic vasculitides: fiction or real need?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 152-159.	0.8	4
113	Fatal hepatitis B virus reactivation due to a lamivudine mutant despite undetectable initial viral load. European Journal of Gastroenterology and Hepatology, 2011, 23, 109.	1.6	3
114	Development of an ANCA-Associated Vasculitides Patient Registry in Greece. Mediterranean Journal of Rheumatology, 2019, 31, 84.	0.8	3
115	Poststreptococcal reactive arthritis with thoracic spine involvement in an adult. Journal of Rheumatology, 2005, 32, 2002-5.	2.0	3
116	Acute splenic sequestration crisis (ASSC) in an adult patient with $\hat{1}^2$ -thalassemia sickle cell disease: a life-threatening complication. Annals of Hematology, 2008, 87, 499-500.	1.8	2
117	Quantitative HBsAg titer as predictor of response to therapy. Current Hepatitis Reports, 2009, 8, 169-172.	0.3	2
118	HCV Treatments and Their Integration Into Rheumatology. Current Rheumatology Reports, 2015, 17, 51.	4.7	2
119	Severe pancytopenia and splenomegaly associated with felty's syndrome, both fully responsive solely to corticosteroids. Clinical Case Reports (discontinued), 2018, 6, 509-512.	0.5	2
120	Evaluation of liver fibrosis by transient elastography (FibroScan $\hat{A}^{\text{@}}$ ) in rheumatic patients during methotrexate treatment. Mediterranean Journal of Rheumatology, 2016, 27, 40-47.	0.8	2
121	Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece. Mediterranean Journal of Rheumatology, 2018, 29, 103-105.	0.8	2
122	A case of adenoviral covid-19 vector vaccine possibly linked to severe but reversible interstitial lung injury post-vaccination. Infectious Diseases, 2022, 54, 692-697.	2.8	2
123	Performance Characteristics of Microparticle Enzyme and Chemiluminescence Immunoassays for Measurement of Anti-HBc Immunoglobulin M in Sera of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection. Vaccine Journal, 2008, 15, 385-387.	3.1	1
124	Infectious arthritis and immune dysfunction. Current Opinion in Rheumatology, 2008, 20, 442.	4.3	1
125	Current treatment options for HBV infection. Current Hepatitis Reports, 2009, 8, 26-30.	0.3	1
126	ECG Changes Mimicking Myocardial Infarction. American Journal of Medicine, 2010, 123, 996-998.	1.5	1

#	Article	IF	CITATIONS
127	The safety of anti-TNF therapy in patients with hepatitis B and C virus infection. International Journal of Clinical Rheumatology, 2012, 7, 191-196.	0.3	1
128	What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B. Current Hepatitis Reports, 2012, 11, 65-69.	0.3	1
129	Recurrent ventricular arrhythmia in a patient with aortitis and myocardial inflammation due to possible immunoglobulin G4â€related disease. Internal Medicine Journal, 2018, 48, 598-601.	0.8	1
130	Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. Journal of Viral Hepatitis, 2021, 28, 1710-1718.	2.0	1
131	Hepatitis C Infection and Vasculitis. , 2004, , 189-200.		1
132	Rheumatologic aspects of viral infections. , 2015, , 912-917.		1
133	Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs. Mediterranean Journal of Rheumatology, 2017, 28, 164-168.	0.8	1
134	Rheumatoid Arthritis-associated Interstitial Lung Disease in Greece: A Multicentre Epidemiological and Clinical Study. Mediterranean Journal of Rheumatology, 2018, 29, 236-239.	0.8	1
135	Twenty Years of Targeted Treatment in Rheumatoid Arthritis in the Greek Databases: Achievements and Unmet Needs. Mediterranean Journal of Rheumatology, 2019, 30, 141.	0.8	1
136	2018 Position Paper on Biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists. Mediterranean Journal of Rheumatology, 2019, 30, 82.	0.8	1
137	Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. Mediterranean Journal of Rheumatology, 2020, 31, 163.	0.8	1
138	Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic. Mediterranean Journal of Rheumatology, 2020, 31, 295.	0.8	1
139	Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined Dermatology–Rheumatology clinic: a retrospective real-world study. Rheumatology International, 2022, , 1.	3.0	1
140	Distal renal tubular acidosis and nephrocalcinosis as initial manifestation of primary sjögren's syndrome Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2021, 32, 1470-1474.	0.3	1
141	Cytochrome P450 enzyme polymorphisms and treatment-related ovarian toxicity in patients with SLE. Nature Clinical Practice Rheumatology, 2007, 3, 492-493.	3.2	0
142	Cryoglobulinemia., 2009,, 269-273.		0
143	Vasculitides and Hepatitis C Infection. , 2015, , 773-791.		0
144	03.16â€Regulatory t cells restrain autophagy in dendritic cells to ameliorate autoimmunity in a ctla4 dependent fashion. , 2017, , .		0

#	Article	IF	CITATIONS
145	Individual Drugs in Rheumatology and theÂRisk of Infection. , 2018, , 445-464.		O
146	FRIO444â€EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS FOLLOWING INADEQUATE RESPONSE TO SYNTHETIC OR BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN REAL-LIFE SETTINGS., 2019,,.		0
147	AB0375â€HYPOGAMMAGLOBULINEMIA AFTER RITUXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS IS NOT RARE AND IS ASSOCIATED WITH BETTER RESPONSE. , 2019, , .		O
148	Editorial: Infection-Related Rheumatic Diseases. Frontiers in Medicine, 2021, 8, 779773.	2.6	0
149	The Complex Management of Viral-Related Autoimmune Diseases. , 2011, , 345-357.		O
150	54-year-old woman with aortic dissection and paraparesis due to aortitis. Mediterranean Journal of Rheumatology, 2016, 27, 29-30.	0.8	0
151	Mitophagy Balance in Various Cell Subsets in Patients with ANCA-Associated Vasculitis and Correlation with the Presence of Anti-Neutrophil Cytoplasmic Antibodies. Mediterranean Journal of Rheumatology, 2020, 31, 366.	0.8	0
152	The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study. Rheumatology International, 2022, 42, 639-650.	3.0	0